Skip to main content

Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.

Publication ,  Journal Article
Penson, DF; Armstrong, AJ; Concepcion, RS; Agarwal, N; Olsson, CA; Karsh, LI; Dunshee, CJ; Duggan, W; Shen, Q; Sugg, J; Haas, GP; Higano, CS
Published in: Prostate Cancer Prostatic Dis
February 2022

BACKGROUND: In the phase 2, randomized, double-blind STRIVE trial, enzalutamide significantly reduced the risk of prostate cancer progression or death versus bicalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) and nonmetastatic CRPC (nmCRPC). The objective of this protocol-specified subgroup analysis of STRIVE was to investigate the benefit of enzalutamide versus bicalutamide specifically in patients with nmCRPC. METHODS: Patients (N = 139) were stratified by disease stage and randomized to enzalutamide 160 mg/day plus androgen deprivation therapy (ADT; n = 70) or bicalutamide 50 mg/day plus ADT (n = 69). RESULTS: Baseline characteristics of patients with nmCRPC were comparable between groups. At a median of 17 months follow-up, enzalutamide reduced the risk of progression or death by 76% versus bicalutamide in patients with nmCRPC (hazard ratio [HR], 0.24; 95% CI 0.14-0.42). Enzalutamide reduced risk of prostate-specific antigen progression by 82% versus bicalutamide in patients with nmCRPC (HR, 0.18; 95% CI 0.10-0.34). The most frequently reported adverse events by patients receiving enzalutamide were fatigue (36.2%), hot flush (20.3%), decreased appetite (17.4%), dizziness (17.4%), and nausea (17.4%). CONCLUSIONS: This STRIVE subgroup analysis of patients with nmCRPC illustrates the benefit of enzalutamide in reducing the risk of progression or death versus bicalutamide in patients with nmCRPC. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT01664923.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Prostate Cancer Prostatic Dis

DOI

EISSN

1476-5608

Publication Date

February 2022

Volume

25

Issue

2

Start / End Page

363 / 365

Location

England

Related Subject Headings

  • Urology & Nephrology
  • Treatment Outcome
  • Tosyl Compounds
  • Prostatic Neoplasms, Castration-Resistant
  • Phenylthiohydantoin
  • Nitriles
  • Male
  • Humans
  • Benzamides
  • Anilides
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Penson, D. F., Armstrong, A. J., Concepcion, R. S., Agarwal, N., Olsson, C. A., Karsh, L. I., … Higano, C. S. (2022). Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. Prostate Cancer Prostatic Dis, 25(2), 363–365. https://doi.org/10.1038/s41391-021-00465-7
Penson, David F., Andrew J. Armstrong, Raoul S. Concepcion, Neeraj Agarwal, Carl A. Olsson, Lawrence I. Karsh, Curtis J. Dunshee, et al. “Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.Prostate Cancer Prostatic Dis 25, no. 2 (February 2022): 363–65. https://doi.org/10.1038/s41391-021-00465-7.
Penson DF, Armstrong AJ, Concepcion RS, Agarwal N, Olsson CA, Karsh LI, et al. Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):363–5.
Penson, David F., et al. “Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.Prostate Cancer Prostatic Dis, vol. 25, no. 2, Feb. 2022, pp. 363–65. Pubmed, doi:10.1038/s41391-021-00465-7.
Penson DF, Armstrong AJ, Concepcion RS, Agarwal N, Olsson CA, Karsh LI, Dunshee CJ, Duggan W, Shen Q, Sugg J, Haas GP, Higano CS. Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):363–365.

Published In

Prostate Cancer Prostatic Dis

DOI

EISSN

1476-5608

Publication Date

February 2022

Volume

25

Issue

2

Start / End Page

363 / 365

Location

England

Related Subject Headings

  • Urology & Nephrology
  • Treatment Outcome
  • Tosyl Compounds
  • Prostatic Neoplasms, Castration-Resistant
  • Phenylthiohydantoin
  • Nitriles
  • Male
  • Humans
  • Benzamides
  • Anilides